MedTrace Logo

REduction of Contrast Via DyeVert Used in CTO Procedures

NCT03118544 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2018-05-17

No results posted yet for this study

Summary

The is an observational, prospective study to evaluate the effect of the DyeVert System on contrast volume administration in patients undergoing clinically-indicated chronic total occlusion (CTO) percutaneous coronary intervention (PCI)

Conditions

  • Chronic Total Occlusion of Coronary Artery

Interventions

DEVICE

DyeVert System

The DyeVert System (Osprey Medical, Inc) consists of a Contrast Monitoring Wireless Display (CMW) and the DyeVert Plus Disposable Kit which is inclusive of a disposable single-use sterile Smart Syringe and DyeVert Plus Module.

Sponsors & Collaborators

  • Osprey Medical, Inc

    collaborator INDUSTRY

  • Minneapolis Heart Institute Foundation

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-26
Primary Completion
2018-02-02
Completion
2018-02-02
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03118544 on ClinicalTrials.gov